Deepen Scientific Understanding of Inflammatory & Fibrotic ILDs, Investigate Biomarkers to Stratify Trial Populations and Identify Endpoints Which are Likely to Predict Clinical Success in Your Next Clinical Trial 2022 dawned with an exhilarating update from aTyr pharma that the FDA has granted orphan drug designation for ATYR1923 for the treatment
07-09 March 2022